Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone

Dr. Meletios A. Dimopoulos, MD, National and Kapodistrian University of Athens, explains Ibrutinib & Rituximab is a new standard for WM Design trials that use the combination as a backbone at ASCO 201... Author: Annual-Meeting Added: 06/04/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts